No phaseCompleted
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients: A Prospective Analysis
- Sponsor
- Universidade do Porto (Academic or other)
- Enrollment
- 55 enrolled
- Conditions
- Heart Failure; Anemia
- Interventions
- Oral iron supplementation
- Ages
- adults, older adults
- Registry
- NCT07708025
Full record on ClinicalTrials.gov
From the registry
People with heart failure often have anemia caused by low iron levels. Ongoing inflammation in heart failure can impair iron absorption, making oral iron therapy less effective. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are medications used to treat heart failure. In addition to their cardiovascular benefits, these drugs may improve iron metabolism and support red blood cell production. This study evaluates whether patients with heart failure and iron deficiency anemia who are receiving SGLT2i therapy respond to treatment with oral iron. Participants receive oral iron for three to four months, followed by a short period without treatment. Blood tests are used to assess changes in hemoglobin levels. The objective of this study is to determine whether treatment with SGLT2i enhances the response to oral iron in patients with heart failure and iron deficiency anemia.
Primary outcomes
- Change in Hemoglobin Levels
History
Last registry update
Registered
Study completion
Primary completion
Started